Roulot D, et al. - Researchers examined the efficacy of daclatasvir (DCV), asunaprevir (ASV), pegylated interferon and ribavirin (Peg-IFN/RBV) association in nonresponder patients infected by hepatitis C virus (HCV) genotype 4 (GT4). As per the outcomes, independent of the cirrhotic status or the GT4 subtype, association of DCV plus ASV and peg-IFN/RBV for 24 weeks showed a high rate of sustained virologic response at post-treatment week 12 (SVR12) in HCV GT4-infected prior nonresponders. Even in cirrhotic patients, the safety profile was acceptable.